Clinical Trial Update: Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab combined with chemotherapy for poorly chemo-responsive thyroid and salivary gland cancers is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer
• Thyroid Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Chicago | Conditions: Thyroid Cancer, Salivary Gland Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING